Abstract
Despite recent advances, the effects of immune-modulating biologic therapies on the clinical course of COVID-19 remains unclear. There are heightened concerns of an increased risk of SARS-CoV-2 infection in patients with atopic diseases who are receiving treatment with dupilumab, an interleukin (IL)-4-alpha receptor antagonist that inhibits signalling from the inflammatory cytokines IL-4 and IL-13. In this study, we investigated the incidence and prognostic outcomes of COVID-19 in patients with atopic diseases undergoing treatment with dupilumab from 5 tertiary academic centers and 7 community practices across Canada.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
